Business Context and Reporting Period
Company: NeuroOne Medical Technologies Corp (NMTC)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and nine months ended June 30, 2024
Business Overview: NeuroOne develops thin film electrode technology for continuous electroencephalogram (cEEG), stereoelectrocencephalography (sEEG), and ablation solutions for neurological disorders. The company holds FDA 510(k) clearance for its Evo cortical electrodes, Evo sEEG electrodes, and OneRF ablation system. Commercial sales of cEEG and sEEG products are distributed via Zimmer, Inc., while the OneRF system launched commercially in March 2024 without a distribution partner.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2024 |
Nine Months Ended June 30, 2024 |
Nine Months Ended June 30, 2023 |
|---|---|---|---|
| Product Revenue | $825,776 | $3,180,719 | $1,210,661 |
| Collaborations Revenue | $0 | $0 | $1,455,188 |
| Total Revenue | $825,776 | $3,180,719 | $2,665,849 |
| Product Gross Profit | $281,872 | $938,605 | $262,862 |
| Gross Margin (Product) | 34.1% | 29.5% | 21.7% |
| Net Loss | $(2,767,525) | $(8,967,515) | $(8,724,370) |
| Net Loss Per Share (Basic/Diluted) | $(0.10) | $(0.35) | $(0.52) |
| Cash and Cash Equivalents (As of June 30, 2024) |
$1,619,977 | ||
| Accumulated Deficit (As of June 30, 2024) |
$(71,653,818) |
Material Changes vs. Prior Period
- Revenue Growth: Product revenue increased 31% quarter-over-quarter (QoQ) and 163% year-over-year (YoY) for the nine-month period, driven by higher sales volume of Strip/Grid, sEEG, and the new OneRF ablation system.
- Collaboration Revenue Cessation: Collaborations revenue dropped to zero for the nine months ended June 30, 2024, compared to $1.46 million in the prior year period. This is due to the completion of all performance obligations under the Zimmer Development Agreement by December 31, 2022.
- Expense Reduction: Research and Development (R&D) expenses decreased by 37% QoQ and 23% YoY (nine months), attributed to the transition of products from development to commercialization phases.
- Liquidity Decline: Cash and cash equivalents decreased from $5.32 million at September 30, 2023, to $1.62 million at June 30, 2024, reflecting a net cash burn of $3.7 million over the nine-month period.
Outlook, Risks, and Subsequent Events
- Going Concern: Management has raised substantial doubt about the company's ability to continue as a going concern. The company relies on future equity or debt financing to fund operations beyond July 2025.
- Recent Financing (Subsequent Events): On August 2, 2024, the company closed a private placement raising approximately $2.65 million and entered into a delayed draw term loan facility of up to $3.0 million.
- Nasdaq Compliance: The company received a notice from Nasdaq on July 11, 2024, regarding non-compliance with the minimum bid price requirement (stock trading below $1.00 for 30 consecutive days). The company has until January 7, 2025, to regain compliance or face potential delisting.
- Customer Concentration: Through March 31, 2024, one customer (Zimmer) accounted for all product and collaboration revenue. While two new customers were added for OneRF sales in Q2 2024, concentration risk remains high.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $1.6 million cash balance plus the $2.65 million private placement proceeds to cover operating expenses until the next funding round.
- Nasdaq Status: Monitor the stock price to ensure it meets the $1.00 minimum bid price requirement for 10 consecutive trading days before January 7, 2025, to avoid delisting.
- OneRF Commercialization: Assess the traction of the OneRF ablation system launched in March 2024, as it is the first product not reliant on the Zimmer distribution agreement.
- Debt Covenants: Review the terms of the new $3.0 million term loan facility, including interest rates (10% per annum) and covenants, to understand future cash flow obligations.
- Revenue Sustainability: Evaluate whether product revenue growth can offset the loss of collaboration revenue and sustain operations without further dilution.